Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04617002 |
|
Expanded Access Status :
Available
First Posted : November 5, 2020
Last Update Posted : May 10, 2024
|
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment |
|---|---|
| Glioma H3 K27M | Drug: ONC201 (dordaviprone) |
| Study Type : | Expanded Access |
| Expanded Access Type : | Intermediate-size Population |
| See clinical trials of the intervention/treatment in this expanded access record. | |
| Official Title: | Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas |
- Drug: ONC201 (dordaviprone)
ONC201 (dordaviprone) is a ClpP agonist and DRD2 antagonist.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 0 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
Inclusion Criteria:
-
Patient meets one or more of the criteria below:
Arm A: Closed to further enrollment. Arm B: Diffuse intrinsic pontine glioma (DIPG), defined as tumors with a pontine epicenter and diffuse involvement of the pons. H3 K27M status does not have to be known or positive for this arm.
Arm C: Patients with primary spinal glioma that is positive for the H3 K27M mutation (performed in a laboratory with CLIA or equivalent certification). Primary spinal glioma must be documented in radiology reporting.
OR Patients with diffuse glioma that is positive for the H3 K27M mutation (performed in a laboratory with CLIA or equivalent certification) AND radiographic evidence of leptomeningeal disease. Leptomeningeal disease must be documented in radiology reporting.
Arm D: Closed to further enrollment. Arm E: Patients with H3 K27M-mutant glioma or midline glioma of unknown H3 K27M mutational status who received ONC201 and/or ONC206 from an alternative (non-Chimerix) source prior to 31 December 2023 as evidenced by documentation (such as pharmacy receipts). Other examples may be confirmed by medical monitor. Detection of H3 K27M mutation should be performed in a CLIA-certified or equivalent laboratory.
Arm F: Patients with H3 K27M-mutant diffuse glioma or midline glioma with unknown H3 K27M mutational status who have completed frontline radiotherapy prior to 31 December 2023. Detection of H3 K27M mutation should be performed in a CLIA-certified or equivalent laboratory.
-
Disease Status:
Arm B: Patient is not required to have radiographic or clinical evidence of progressive disease.
Arm C: Patient must have progressive disease as defined by RANO criteria or have documented recurrent glioma on diagnostic biopsy.
Arm E: Not Applicable. Arm F: Patient must have progressive disease as defined by RANO criteria or have documented recurrent glioma on diagnostic biopsy.
-
Prior Radiotherapy:
Arm B: Patient must be at least 14 days from completion of radiotherapy. Arm C: Patient must be at least 90 days from completion of radiotherapy and at least 14 days from reirradiation if applicable.
Arm E: Not applicable. Arm F: Patient must be at least 90 days from completion of frontline radiotherapy and at least 14 days from reirradiation if applicable.
- (Not applicable; criterion removed in Version 5).
- Patient must weigh at least 10kg.
-
Washouts:
Arm B, C & F: From the projected start of scheduled study treatment, the following time periods must have elapsed from prior anti-cancer treatments: 5 half-lives from any investigational agent, 4 weeks from cytotoxic therapy (except 23 days for temozolomide and 6 weeks from nitrosoureas), 6 weeks from anti-cancer antibodies (no washout required for bevacizumab), 4 weeks (or 5 half-lives, whichever is shorter) from other anti-tumor therapies, and 1 week from devices used to treat cancer.
Arm E: No washouts are required for ONC021 and ONC206. All other anti-cancer agents need to be discontinued prior to enrollment with the exception of bevacizumab.
- Arm B, C & F: MRI of patient's glioma obtained within 28 days prior to the start of study drug. Arm E: MRI will be obtained within 8 weeks prior to enrollment
-
Adequate organ and marrow function as defined below:
- Absolute neutrophil count ≥1,000/mm3 without growth factor use ≤7 days prior to treatment (Cycle 1 Day 1 [C1D1])
- Hemoglobin ≥8.0 mg/dL without red blood cell transfusion ≤3 days prior to C1D1
- Total serum bilirubin ≤ 1.5 X upper limit of normal (ULN)
- AST (SGOT)/ALT (SGPT) ≤2 X ULN; ≤5 X ULN if there is liver involvement secondary to tumor.
- Serum creatinine ≤1.5 X ULN (OR creatinine clearance ≥60mL/min/1.73m2) Arm E: Patients with organ and marrow function values outside the defined criteria must be approved by medical monitor.
- For patients post pubertal: Female patients must agree to use effective contraception while taking ONC201 and for at least 90 days after completion of treatment. Male patients must be surgically sterile or must agree to use effective contraception while taking ONC201 and for at least 90 days after completion of treatment. The decision of effective contraception will be based on the judgment of the principal investigator.
- Ability to understand a written informed consent document, and the willingness to sign it. Assent will be obtained when appropriate based on the patient's age.
Exclusion Criteria:
- Qualifies for participation in an ongoing ONC201 or ONC206 clinical trial.
-
Arm B, C & F: Previously or current enrollment in an ONC201 clinical study (including open-label and blinded studies) or expanded access protocol or previous exposure to ONC201 from any other source for treatment of CNS tumor.
Arm E: Previous or current enrollment in an ONC201 clinical study (including open-label and blinded studies) or expanded access protocol for the treatment of CNS tumor.
- Arms B, C, E & F: Current or planned participation in a study of an investigational agent (including ONC206) or using an investigational device.
- (Not applicable; criterion removed in Version 4).
- Any known systemic infection that, in the opinion of the investigator, could compromise the safety of the patient while taking ONC201.
- Prolongation of QT/QTcF interval (QTc interval >480 milliseconds) using Fridericia's QT correction formula on two ECGs separated by at least 2 days.
- A history of Torsades de Pointes or heart failure, hypokalemia, or family history of prolonged QT Syndrome
- Concomitant use of medication(s) known to prolong the QT/QTc interval.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04617002
| Contact: Rohinton Tarapore, PhD | 1-919-806-1074 | clinicaltrials@chimerix.com |
Show 24 study locations
| Responsible Party: | Chimerix |
| ClinicalTrials.gov Identifier: | NCT04617002 |
| Other Study ID Numbers: |
ONC028 |
| First Posted: | November 5, 2020 Key Record Dates |
| Last Update Posted: | May 10, 2024 |
| Last Verified: | March 2024 |
|
Glioma Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type |
Neoplasms Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue TIC10 compound Antineoplastic Agents |